Condition (MeSH)
Severe Acute Respiratory Syndrome
ClinicalTrials.gov lists 357 trials for Severe Acute Respiratory Syndrome or a narrower condition beneath it. National Institute of Allergy and Infectious Diseases (NIAID) has the most among industry and government lead sponsors, with 20.
Search trials, drugs, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.
Trials per phase
1 more section with rows
357 of the 357 trials are tagged with Severe Acute Respiratory Syndrome itself; the rest are tagged with a narrower condition beneath it.
When did Severe Acute Respiratory Syndrome trials start? (13)
Shown in this order: most recent first, 1990 onwards. 2026 is partial: trials registered with a 2026 start date so far, not a full year.
Trials over time, by phase
- Phase 1
- Phase 1/2
- Phase 2
- Phase 2/3
- Phase 3
- Phase 4
- Not applicable
- Observational
Top of scale: 225
Trials registered with a start date in each year, 1990 onward, stacked by phase (complete years only; the current partial year is in the table's notes). The table below lists the same counts, most recent years first.
| Year | Trials started |
|---|---|
| 2026 (partial year) | 3 |
| 2025 | 2 |
| 2024 | 3 |
| 2023 | 7 |
| 2022 | 7 |
| 2021 | 89 |
| 2020 | 225 |
| 2018 | 2 |
| 2016 | 2 |
| 2009 | 2 |
Showing 10 of 13 earlier years.
Forecast of the full-year count, planned starts included, not rows of this table: about 4 trials starting in 2026 and about 3 in 2027, the average of the 24 months through September, counted as registered and carried forward. The rows of this table count trials registered so far with a start date in the year, planned starts included; the forecast looks ahead to the count for the whole year, so it is not the same measure. In backtests on conditions of this size, forecasts made part-way through the year were typically off by about 28 percent and ran about 20 percent low against the count later registered; forecasts made before the year began were off by about 39 percent and ran about 37 percent low against the count later registered. These figures rest on a few years of history (target years from 2018 to 2025, varying by figure), place each condition as it is mapped today rather than as it was then, and score against a count for the newest year that was still being revised. Only condition series were scored.
Prediction, not a registry value: median of 22 months from start to primary completion across 17 trials still running at the 2026-10-09 snapshot; registered median of 9 months across 251 trials with a primary completion typed Actual. Source: ClinicalTrials.gov / AACT (CTTI), public domain.
What phase are Severe Acute Respiratory Syndrome trials in? (9)
Shown in this order: phase order.
Show the trials by phase as a table
| Phase | Trials |
|---|---|
| Phase 1 | 23 |
| Phase 1/2 | 13 |
| Phase 2 | 57 |
| Phase 2/3 | 8 |
| Phase 3 | 58 |
| Phase 4 | 10 |
| Not applicable | 52 |
| Observational | 131 |
| Expanded access | 5 |
How many Severe Acute Respiratory Syndrome trials are recruiting? (11)
Shown in this order: the order a trial moves through, from not yet recruiting to unknown.
| Status | Trials |
|---|---|
| Not yet recruiting | 3 |
| Recruiting | 3 |
| Enrolling by invitation | 1 |
| Active, not recruiting | 1 |
| Available | 1 |
Showing 5 of 11 statuses.
Status as registered on ClinicalTrials.gov. Each trial is counted once.
Which lead sponsors run the most Severe Acute Respiratory Syndrome trials? (8)
Shown in this order: most trials first. Lead sponsors the registry classes as industry, NIH, US federal, other government or network. A hospital or university the registry files as government can appear here. Sponsors it classes as academic or other are shown on the full page, because that class cannot separate an institution from a named investigator.
| Sponsor | Trials |
|---|---|
| National Institute of Allergy and Infectious Diseases (NIAID) | 20 |
| CureVac | 5 |
| Institut Pasteur | 5 |
| Lahore General Hospital | 5 |
| Applied Biology, Inc. | 4 |
Showing 5 of 8 sponsors.
Which drugs are being tested for Severe Acute Respiratory Syndrome? (7)
Shown in this order: most trials first. One row per drug, matched to a single molecule under all its names, ranked by number of trials.
| Drug | Trials |
|---|---|
| Remdesivir | 13 |
| Ivermectin | 5 |
| Camostat | 4 |
| Corticosteroid | 4 |
| Vitamin C | 4 |
Showing 5 of 7 drugs.
Interventions as named in the registry (8)
Shown in this order: most trials first.
| Drug | Trials |
|---|---|
| Hydroxychloroquin | 13 |
| Convalesscent Plasma | 6 |
| Low dose losartan | 4 |
| CVnCoV Vaccine | 4 |
| tocilizumab SC | 3 |
Showing 5 of 8 interventions.
These are the names sponsors entered on ClinicalTrials.gov that we have not matched to a single molecule. Some are drugs under a brand or code name; others are procedures, doses or arm labels.
Which serious adverse events do Severe Acute Respiratory Syndrome trials report? (10)
Shown in this order: most subjects affected first. Subjects affected summed across trials, a cross-trial signal, not a rate.
| Adverse event | Subjects affected | Trials |
|---|---|---|
| Respiratory failure | 223 | 19 |
| Death | 203 | 5 |
| COVID-19 pneumonia | 166 | 10 |
| Pneumothorax | 88 | 18 |
| Acute kidney injury | 83 | 15 |
Showing 5 of 10 adverse events.
Which publications cover Severe Acute Respiratory Syndrome? (373)
Shown in this order: major-topic papers first, then newest, then most linked to trials.
| Publication | Journal | Year | Major topic |
|---|---|---|---|
| Current views on the potentials of convalescent plasma therapy (CPT) as Coronavirus disease 2019 (COVID-19) treatment: A systematic review and meta-analysis based on recent studies and previous respiratory pandemics. | Reviews in medical virology | 2021 | Yes |
| An Impaired Inflammatory and Innate Immune Response in COVID-19. | Molecules and cells | 2021 | Yes |
| In Vitro Antiviral Activity and Projection of Optimized Dosing Design of Hydroxychloroquine for the Treatment of Severe Acute Respiratory Syndrome Coronavirus 2 (SARS-CoV-2). | Clinical infectious diseases : an official publication of the Infectious Diseases Society of America | 2020 | Yes |
| A new coronavirus associated with human respiratory disease in China. | Nature | 2020 | Yes |
| Angiotensin-converting enzyme 2 (ACE2) as a SARS-CoV-2 receptor: molecular mechanisms and potential therapeutic target. | Intensive care medicine | 2020 | Yes |
Showing 5 of 373 publications.
Prevalence (6)
Shown in this order: jurisdiction, then disease name. Orphanet observation for the mapped ORPHA concept; the mapping relation column says whether that concept is exactly this condition or broader or narrower.
| Orphanet disease | Type | Class | Geography | Jurisdiction | Mapping relation |
|---|---|---|---|---|---|
| Severe acute respiratory syndrome | Point prevalence | Unknown | Worldwide | Not stated | Unspecified |
| Severe acute respiratory syndrome | Point prevalence | Unknown | Worldwide | Not stated | Exact |
| Severe acute respiratory syndrome | Annual incidence | <1 / 1 000 000 | Europe | Not stated | Exact |
| Severe acute respiratory syndrome | Annual incidence | <1 / 1 000 000 | Europe | Not stated | Unspecified |
| Severe acute respiratory syndrome | Point prevalence | Unknown | Worldwide | Not stated | Exact |
Showing 5 of 6 prevalence observations.
Rare-disease identity (2)
Shown in this order: exact, broader, narrower, other.
| Orphanet disease | ORPHA code | Relation | Source |
|---|---|---|---|
| Severe acute respiratory syndrome | 140896 | Exact | Orphadata Science knowledge files, Product 1 |
| Severe acute respiratory syndrome | 140896 | Exact | Orphanet Rare Disease Ontology (ORDO) |
Not on this page
Not measured: delivery record.
Checked, with nothing recorded for this condition: sub-conditions in mesh.